Vanda Competitors
| VNDA Stock | USD 7.23 0.37 4.87% |
Vanda Pharmaceuticals vs Capricor Therapeutics Correlation
Very poor diversification
The correlation between Vanda Pharmaceuticals and CAPR is 0.81 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Vanda Pharmaceuticals and CAPR in the same portfolio, assuming nothing else is changed.
Moving together with Vanda Stock
Moving against Vanda Stock
| 0.91 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.83 | GNLX | Genelux Common | PairCorr |
| 0.8 | EDIT | Editas Medicine | PairCorr |
| 0.78 | ABP | Abpro Holdings | PairCorr |
| 0.76 | DWTX | Dogwood Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vanda Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vanda Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Vanda Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Vanda and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Vanda Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Vanda Stock performing well and Vanda Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vanda Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ACHV | 3.14 | (0.39) | 0.00 | (0.10) | 0.00 | 5.86 | 25.05 | |||
| TRDA | 2.84 | 0.71 | 0.25 | 1.70 | 2.38 | 6.65 | 15.00 | |||
| HUMA | 3.75 | (0.81) | 0.00 | (0.31) | 0.00 | 8.16 | 20.54 | |||
| VYGR | 2.48 | (0.30) | 0.00 | (0.22) | 0.00 | 4.58 | 19.71 | |||
| AVIR | 2.26 | 0.36 | 0.09 | 0.63 | 3.11 | 5.54 | 17.79 | |||
| ARCT | 3.04 | (0.39) | 0.00 | (0.24) | 0.00 | 6.10 | 15.98 | |||
| ALLO | 4.11 | 0.65 | 0.14 | 0.44 | 4.01 | 12.38 | 26.97 | |||
| SGMT | 3.21 | (0.29) | 0.00 | (1.05) | 0.00 | 6.08 | 23.02 | |||
| IMRX | 3.93 | (0.12) | 0.00 | 0.22 | 0.00 | 8.12 | 67.18 | |||
| CAPR | 12.18 | 5.09 | 0.89 | 0.68 | 4.33 | 11.51 | 386.29 |
Cross Equities Net Income Analysis
Compare Vanda Pharmaceuticals and related stocks such as Achieve Life Sciences, Entrada Therapeutics, and Humacyte Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACHV | (8.9 M) | (14.7 M) | (21.1 M) | (31.8 M) | (26.2 M) | (16.8 M) | (20.1 M) | (10.6 M) | (12.7 M) | (16.1 M) | (14.7 M) | (32.9 M) | (41.9 M) | (29.8 M) | (39.8 M) | (35.8 M) | (34.1 M) |
| TRDA | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (26.5 M) | (50.1 M) | (87.5 M) | (6.7 M) | 65.6 M | 75.5 M | 79.2 M |
| HUMA | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (66.5 M) | (26.5 M) | (12 M) | (110.8 M) | (148.7 M) | (133.8 M) | (127.1 M) |
| VYGR | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (16.3 M) | (29.7 M) | (40.2 M) | (70.7 M) | (88.3 M) | (40.8 M) | 36.7 M | (66 M) | (46.4 M) | 132.3 M | (65 M) | (74.8 M) | (71 M) |
| AVIR | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (13.5 M) | (10.9 M) | 121.2 M | (115.9 M) | (136 M) | (168.4 M) | (151.5 M) | (144 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.6 M) | (10.5 M) | (32.8 M) | (19.4 M) | (24.6 M) | (10.9 M) | (21.8 M) | (26 M) | (72.1 M) | (203.7 M) | 9.3 M | (29.7 M) | (80.9 M) | (72.8 M) | (69.2 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (211.5 M) | (184.6 M) | (233.5 M) | (244.8 M) | (329.8 M) | (327.3 M) | (257.6 M) | (231.8 M) | (243.4 M) |
| SGMT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (11.4 M) | (24.4 M) | (30.5 M) | (27.9 M) | (45.6 M) | (41 M) | (43.1 M) |
| IMRX | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (17 M) | (33.5 M) | (50.5 M) | (53.5 M) | (61 M) | (54.9 M) | (57.7 M) |
| CAPR | (200) | (4.9 M) | (1.9 M) | (8.9 M) | (6.2 M) | (12.9 M) | (18.8 M) | 2.4 M | (15.2 M) | (7.6 M) | (13.7 M) | (20 M) | (29 M) | (22.3 M) | (40.5 M) | (36.4 M) | (34.6 M) |
Vanda Pharmaceuticals and related stocks such as Achieve Life Sciences, Entrada Therapeutics, and Humacyte Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Vanda Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Vanda Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Vanda Pharmaceuticals Competitive Analysis
The better you understand Vanda Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Vanda Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Vanda Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Vanda Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Vanda Pharmaceuticals Competition
Vanda Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Vanda Pharmaceuticals in relation to its competition. Vanda Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Vanda Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Vanda Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Vanda Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Vanda Pharmaceuticals position
In addition to having Vanda Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sports Thematic Idea Now
Sports
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Vanda Pharmaceuticals Correlation with its peers. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vanda Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.96) | Earnings Share (1.44) | Revenue Per Share | Quarterly Revenue Growth 0.181 | Return On Assets |
Understanding Vanda Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Vanda's accounting equity. The concept of intrinsic value - what Vanda Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Vanda Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vanda Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.